Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452376 | 1.00 | PRMT5 (0.37) | PRMT5WDR77BACE1BACE2SLC9A1 | |
| SCHEMBL13310395 | 1.00 | PRMT5 (0.37) | PRMT5WDR77BACE1BACE2SLC9A1 | |
| SCHEMBL30685342 | 0.84 | LIPG (0.40) | SLC9A1LIPGLPLROCK1 | |
| SCHEMBL22280755 | 0.84 | LIPG (0.40) | SLC9A1LIPGLPLROCK1 | |
| SCHEMBL26363672 | 0.84 | LIPG (0.40) | SLC9A1LIPGLPLROCK1 | |
| SCHEMBL22273384 | 0.84 | LIPG (0.40) | SLC9A1LIPGLPLROCK1 | |
| SCHEMBL3448559 | 0.83 | USP30 (0.37) | PRMT5WDR77BACE1BACE2AAK1 | |
| SCHEMBL3448562 | 0.83 | USP30 (0.37) | PRMT5WDR77BACE1BACE2AAK1 | |
| SCHEMBL13310393 | 0.83 | USP30 (0.37) | PRMT5WDR77BACE1BACE2AAK1 | |
| SCHEMBL22264948 | 0.83 | FFAR1 (0.41) | SLC9A1LIPGLPLSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | PRMT5 3689/4885WDR77 4376/4885BACE1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.